



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

Metabolism Clinical and Experimental

journal homepage: www.metabolismjournal.com

Reply to Vitamin D deficiency in COVID-19: mixing up cause and consequence



Dear Editor,

The SARS-Cov-2 tsunami has engulfed the global community into an accelerated search for preventive and therapeutic strategies to halt its devastating toll; immune modulation being the fulcrum of all. The effect of vitamin D role on innate and adaptive immunity is undisputable [1], yet its role in this viral illness is unclear [2]. While biologic plausibility supports an association between vitamin D status and COVID-19 infection, establishing causality remains elusive. It was not implied in our commentary [3]. COVID-19 patients often seek medical advice after the onset of symptoms, and past the trigger of its inflammatory cascade. We concur with Smolders et al., reverse causality is a consideration [4].

These authors show that the inoculation of 9 healthy volunteers with E.Coli-derived lipopolysaccharide, at a relatively high dose of 4 ng/kg over 4 h [5], resulted in a rise in inflammatory markers, and a concomitant drop in mean serum 25-hydroxyvitamin D (25OHD), by 2.6 ng/ml, 2–3 h later [4]. Several other small studies (N 19–90) examined changes in 25OHD in acute illnesses, using for the most part standardized assays. These included elective orthopedic [6,7], and cardiac surgery [8], acute pancreatitis [9], or shock and ICU admissions [10,11]. The drop in mean 25OHD of 1–12 ng/ml occurred during the first 48 h of admission [6–11]. The response was however quite variable, some studies registering no change or an increase [9,12]. Serum 25OHD level may return to baseline within 5–14 days [6,8,9], but this return was not linked to recovery from illness [12]. Both 25OHD and 1,25OH₂D decreased similarly by day 5 in one study, but while 25OHD returned to baseline, there was a subsequent overshoot in 1,25OH₂D level [8].

The reasons for decrements in 25OHD level in acute illness are not clear. The association of CRP and albumin, most frequently assessed predictors for a change in 25OHD during illness, were inconsistent [6–9]. The dilutional effects of fluids during illness [6], a drop in vitamin D binding protein (VDBP) [7], and a possible increase in 1- α hydroxylation of 25OHD [9], may all contribute. Free 25OHD may also be affected. In a study of 33 patients undergoing knee arthroplasty, levels of total and free 25OHD, and VDBP, decreased by 40% and 15%, respectively, starting day 1 post-operatively [6].

The collider effect challenges association studies, reverse causality is one of them [13]. The severity of COVID-19 infection affects the decision for hospitalization, and causal inferences in hospitalized patients might not be well-grounded [13]. A thorough assessment of the evidence available, with particular attention to matters relevant to 25OHD assays [14], reverse causality, and quality assessment, is crucial [15]. Such scrutiny provides the framework to provide guidance on vitamin D supplementation, given in a preventive or adjuvant-therapy mode, in the

spectrum of COVID-19 illnesses. Well conducted observational studies will also provide the basis, when coupled with forthcoming evidence from vitamin D randomized controlled trials where vitamin D effect may be confounded by the standard use of steroids, to confirm or refute the putative role of vitamin D in Covid-19 illnesses.

Declaration of competing interest

None

References

- [1] Koivisto O, Hanel A, Carlberg C. Key vitamin D target genes with functions in the immune system. *Nutrients*. 2020;12(4):1140–58.
- [2] Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol*. 2020;20(6):363–74.
- [3] Chakhtoura M, Napoli N, El Hajj Fuleihan G. Commentary: myths and facts on vitamin D amidst the COVID-19 pandemic. *Metabolism, Clinical and Experimental*. 2020;109:154276.
- [4] Smolders J, van den Ouweland J, Geven C, Pickkers P, Kox M. Vitamin D deficiency in COVID-19: mixing up cause and consequence. *Metabolism, Clinical and Experimental* [In Press].
- [5] Fullerton JN, Segre E, De Maeyer RPH, Maini AAN, Gilroy DW. Intravenous endotoxin challenge in healthy humans: an experimental platform to investigate and modulate systemic inflammation. *J Vis Exp*. 2016;111:53913–21.
- [6] Reid D, Toole BJ, Knox S, Talwar D, Harten J, O'Reilly DSJ, et al. The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. *Am J Clin Nutr*. 2011;93(5):1006–11.
- [7] Waldron JL, Ashby HL, Cornes MP, Bechervaise J, Razavi C, Thomas OL, et al. Vitamin D: a negative acute phase reactant. *J Clin Pathol*. 2013;66(7):620–2.
- [8] Krishnan A, Ochola J, Mundy J, Jones M, Kruger P, Duncan E, et al. Acute fluid shifts influence the assessment of serum vitamin D status in critically ill patients. *Crit Care Med*. 2010;14(6):R216–23.
- [9] Bang UC, Novovic S, Andersen AM, Fenger M, Hansen MB, Jensen J-EB. Variations in serum 25-hydroxyvitamin D during acute pancreatitis: an exploratory longitudinal study. *Endocr Res*. 2011;36(4):135–41.
- [10] Dayal D, Kumar S, Sachdeva N, Kumar R, Singh M, Singhi S. Fall in vitamin D levels during hospitalization in children. *Int J Pediatr*. 2014;2014(2014):291856–62.
- [11] Braun AB, Gibbons FK, Litonjua AA, Giovannucci E, Christopher KB. Low serum 25-hydroxyvitamin D at critical care initiation is associated with increased mortality. *Crit Care Med*. 2012;40(1):63–72.
- [12] Barth JH, Field HP, Mather AN, Plein S. Serum 25 hydroxy-vitamin D does not exhibit an acute phase reaction after acute myocardial infarction. *Ann Clin Biochem*. 2012;49(Pt 4):399–401.
- [13] Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. *Nat Commun*. 2020;11(1):5749–61.
- [14] Heijboer A, Blankenstein M, Kema I, Buijs M. Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitamin D binding protein concentration. *Clin Chem*. 2012;58(3):543–8.
- [15] Bassatne A, Basbous M, Chakhtoura M, Rahme M, El Zein O, El-Hajj Fuleihan G. The link between corona viruses and Vitamin D (VIDD): an extensive and rigorous systematic review and meta-analysis. Available from https://www.crd.york.ac.uk/prosperto/display_record.php?RecordID=203960; 2020.

M. Chakhtoura

Calcium Metabolism and Osteoporosis Program, American University of Beirut Medical Center, Beirut, Lebanon
Scholars in Health Research Program (SHARP), American University of Beirut Medical Center, Beirut, Lebanon

*Corresponding author at: Calcium Metabolism and Osteoporosis Program, American University of Beirut, Medical Center, Beirut, P.O. Box: 113-6044/C8, Lebanon.
E-mail address: mc39@aub.edu.lb
G. El Hajj Fuleihan
Calcium Metabolism and Osteoporosis Program, American University of

Beirut Medical Center, Beirut, Lebanon
Scholars in HeAlth Research Program (SHARP), American University of
Beirut Medical Center, Beirut, Lebanon

2 December 2020